Lilly's next-generation anti-obesity candidate is called retatrutide, and it acts on GLP-1, GIP, and glucagon receptors. In June 2023, Lilly reported phase 2 trial results that showed retatrutide ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide) – but adds in activity against glucagon. That three-pronged attack helped ...

It also reported preliminary data with an oral triple agonist called retatrutide – targeting GLP-1, GIP, and glucagon – that is also being advanced quickly into phase 3. Shares in Pfizer fell ...